In this review:
- Interim results from the PERCEIVE study of voretigene neparvovec
- VP-001 in patients with PRPF31-related retinitis pigmentosa
- Longer durability new-generation therapies for neovascular AMD
- Gene therapy for neovascular AMD
- MacTel2: systemic associations
- Current and upcoming therapies for MacTel2
- H.A.L.T technology lenses slow progression of MOP
- Impact of fetal alcohol disorder on optical development
- AAVB-081 gene therapy for Usher syndrome type 1B retinitis pigmentosa
- Subretinal laru-zova gene therapy for X-linked retinitis pigmentosa
Please login below to download this issue (PDF)